We’ve been appointed to support IDT Biologika, a Contract Development & Manufacturing Organisation (CDMO) based in Dessau-Rosslau, Germany.
IDT Biologika’s expertise spans cell culture and microbial-based proteins, monoclonal antibodies, vaccines, gene and immune therapeutics, biosimilars and other sterile injectables. With more than 100 years of expertise, the company, part of the South Korean SK bioscience family, works with pharmaceutical and biotech companies to develop and commercialise their therapies, bringing life-saving treatments to patients around the world.
With demand for gene and immune therapies rising rapidly, and having identified an unmet need for viral vectors – modified viruses that deliver genetic material into cells – the company is now looking to expand its commercial opportunities in Japan, the world’s third-largest pharmaceutical market, and to build the IDT Biologika brand further in the market.
To support our new client, our Tokyo team will start by identifying and qualifying target pharma and biotech customers in the vaccines and other biologics sector, and by assessing current and future demand for IDT Biologika’s contract services in Japan. We’ll also examine the competitive landscape in the biological CDMO and Contract Research Organisation (CRO) fields, identifying gaps in provision and aligning these with the company’s core strengths.
Our team will then start building a sales pipeline for IDT Biologika, initially in the vaccines and other biologics space, and advise on the strategic opportunities and challenges for the company as it moves forward with its expansion in Japan.
We’ll also support IDT Biologika during its visit to Interphex Week in Tokyo, May 20–22. This will include introducing the company to the Japanese market through its exhibition booth and supporting its presentation during the event.
“At IDT Biologika, our expansion into the Japanese market is driven by what matters most to customers: reliability, quality and trust. As a company ‘Made in Germany’, we’re looking forward to bringing our high quality standards, technological excellence and strict regulatory compliance, as confirmed by our strong track record with FDA, EMA and ANVISA, to potential partners in Japan.”
If you'd like to discuss the prospects for your biotech business in Asia, please contact Carsten Detering at carsten.detering@intralinkgroup.com.
[Images courtesy of IDT Biologika]